Company

Leads Biolabs' LBL‑024 Granted Second FDA Fast Track Designation – Bispecific PD‑L1/4‑1BB Antibody Advances in First‑Line Advanced Biliary Tract Cancer
HKG: 9887Leads Biolabs

Leads Biolabs’ LBL‑024 Granted Second FDA Fast Track Designation – Bispecific PD‑L1/4‑1BB Antibody Advances in First‑Line Advanced Biliary Tract Cancer

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that LBL‑024 has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of advanced…

Novo Nordisk to Withdraw All Forms of Levemir in the UK by End‑2026 – DHSC Issues National Patient Safety Alert Mandating Insulin Switches

Novo Nordisk to Withdraw All Forms of Levemir in the UK by End‑2026 – DHSC Issues National Patient Safety Alert Mandating Insulin Switches

Chai Discovery Announces Collaboration with GSK – AI Protein Folding and Design Platform to Power Drug Discovery Across GSK's Pipeline

Chai Discovery Announces Collaboration with GSK – AI Protein Folding and Design Platform to Power Drug Discovery Across GSK’s Pipeline

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Academic conferenceClinical trial results

Eli Lilly’s Retevmo Shows 83% Risk Reduction in Disease Recurrence for Early-Stage RET Fusion-Positive NSCLC in Phase 3 LIBRETTO-432 Trial

CancerCDE

Teligene’s TL118 Enters NMPA’s SPARK Initiative for Pediatric Cancer Treatment Development

FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline

NASDAQ: SNYPriority reviews

Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease

Show More